amyloid-beta-peptides has been researched along with Polymyalgia-Rheumatica* in 1 studies
1 trial(s) available for amyloid-beta-peptides and Polymyalgia-Rheumatica
Article | Year |
---|---|
Prednisolone (30-60 mg/day) for diseases other than AD decreases amyloid beta-peptides in CSF.
The effect of corticosteroid on the concentration of amyloid beta-peptide (Abeta) in human CSF obtained from 16 patients without dementia treated with prednisolone (> or =30 mg daily) was studied. The concentrations of Abetax-40 and Abetax-42 in CSF decreased after treatment was started (p < 0.002). A moderate- or high-dose regimen of prednisolone decreases Abeta production or increases Abeta degradation in the human brain and deserves further study in AD. Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amyloid beta-Peptides; Brain; Cranial Nerve Diseases; Dose-Response Relationship, Drug; Female; Glucocorticoids; Graves Disease; Humans; Male; Middle Aged; Multiple Sclerosis; Peptide Fragments; Polymyalgia Rheumatica; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Prednisolone | 2002 |